Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy as of July 2023

MARA Rating Company December 16, 2025

Olaparib / lynparza for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer as of January 2024

MARA Rating Company December 16, 2025

Lynparza / olaparib for untreated hormone-relapsed metastatic prostate cancer as of February 2024

MARA Rating Company December 16, 2025

Lynparza / olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy as of March 2024

MARA Rating Company December 16, 2025

Lynparza / olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy as of February 2025

MARA Rating Company December 16, 2025

Onureg / azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy as of October 2022

MARA Rating Company December 16, 2025

Osimertinib / tagrisso for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection as of February 2025

MARA Rating Company December 16, 2025

Osimertinib for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as of May 2025

MARA Rating Company December 16, 2025

Nivolumab / ipilimumab for untreated unresectable malignant pleural mesothelioma as of August 2022

MARA Rating Company December 16, 2025

Nivolumab / opdivo for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma as of January 2023

MARA Rating Company December 16, 2025